Assembly Biosciences (ASMB) FCF Margin (2017 - 2026)
Assembly Biosciences (ASMB) recorded quarterly FCF Margin of 269.28% in Q1 2026, down 904.62% quarter-over-quarter from 33.47% in Q4 2025, and down 2043.0% on a YoY basis from 13.86% in Q1 2025.
Assembly Biosciences (ASMB) FCF Margin (2017 - 2026) Analysis & Trends
Assembly Biosciences' FCF Margin history runs 9 years deep, the most recent figure standing at 269.28% for Q1 2026.
- In Q1 2026, FCF Margin fell 2043.0% year-over-year to 269.28%; the TTM figure through Mar 2026 stood at 56.03% (up 11877.0% YoY), while the FY2025 annual figure was 56.93%, up 12240.0% from the prior year.
- FCF Margin was 269.28% for Q1 2026 at Assembly Biosciences, down from 33.47% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 1027.17% in Q4 2023 to a low of 317.68% in Q1 2024.
- Historically, FCF Margin has averaged 51.87% across 4 years, with a median of 187.34% in 2024.
- The sharpest annual moves came in 2024 and 2025: FCF Margin sank 103270 bps in 2024, then surged 8205 bps in 2025.
- A 4-year view of FCF Margin shows it stood at 1027.17% in 2023, then slumped by 101 bps to 5.53% in 2024, then jumped by 705 bps to 33.47% in 2025, then slumped by 905 bps to 269.28% in 2026.
- The last three FCF Margin figures came in at 269.28% (Q1 2026), 33.47% (Q4 2025), and 140.65% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -3.98% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 43.35% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Assembly Biosciences | 418.96 Mn | 192.36 Mn | - | -269.28% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -269.28% |
| Dec 31, 2025 | 33.47% |
| Sep 30, 2025 | -140.65% |
| Jun 30, 2025 | -174.09% |
| Mar 31, 2025 | -248.85% |
| Dec 31, 2024 | -5.53% |
| Sep 30, 2024 | -222.70% |
| Jun 30, 2024 | -200.59% |
| Mar 31, 2024 | -317.68% |
| Dec 31, 2023 | 1,027.17% |
| Sep 30, 2021 | -301.92% |
| Dec 31, 2020 | -2,436.74% |
| Sep 30, 2020 | 30.76% |
| Jun 30, 2020 | -59.73% |
| Mar 31, 2020 | -619.53% |
| Dec 31, 2019 | -430.94% |
| Sep 30, 2019 | -439.49% |
| Jun 30, 2019 | -683.64% |
| Mar 31, 2019 | -654.49% |
| Dec 31, 2018 | -453.49% |